PainReform Ltd (PRFX) News

I'm out again...was too early...it will have its day by Y/E

PRFX new 52 week low

What the heck is happening here? Capitulation? Ex-CEO Hadar dumping?

Or, in a best case scenario MMs are looking for inventory before a run. Dip and rip is common. Time will tell.

... heading for the promised land...just starting

...all I know is this is way oversold and the product seems to be working...to be honest Im here for a quick trade...I make the big money playing options

We should get a bump, especially if the promising results in April are confirmed (96 hr pain relief Vs. 72 hr, and better performance than the leading competitor product).

But Hadar was saying that after these clinical trials for Bunionectomy (hard tissue) were concluded that they would then do the Hernia operation (soft tissue) clinical trials in 2025 with planned NDA submission in 2026. I wonder if that strategy will change now?

Dont know...doesnt matter as long as the last phase of the drug trial is happening...we should get a bump soon

Interesting that CEO Hadar stepped down. I have no problem with this as I didn’t think he was very good, but I wonder why he made this decision.

I have more confidence in Dr. Ehud Geller as the interim.

Added some today...low enough...dont see any danger of RS...will be past $1 soon enough

PRFX new 52 week low

Think we have to wait for more news on this one...need to know whwn drug trial ends...maybe around Sept

Taking off a little bit now

PRFX new 52 week low

Nice, thank you

That could hapoen but theres still plenty of time on the clock...I sold this a while ago and looking to buy back in a few mos...this will be a good one when it runs

These guys have to do a reverse to get back in compliance? Thanks

Added...low enough

PRFX new 52 lo

Bunionectomy is just one of several applications for this 1st product. The market is actually quite substantial. They are targeting at least 10-12 countries. I’ll be buying more around $0.40.

More new lows to come this afternoon when I return from the supermarket

Bonionectomy??? Isreal.... $4M @ .80????


wow. Not even looking any further on this one.

Surprised this isn't on the otc...


yet

I was stalking your "new 52 week lows"

PRFX new 52 lo

PRFX new 52 lo

PRFX: Looks like company raising funds now through selling of shares, which I don’t mind because they have a good business plan and they’re executing against it.

Buckle up, it’s gonna be a roller coaster ride!

PRFX new 52 lo

What leaked?

PRFX over $3

I'm wrong, only the first half of part 3 are complete...an earlier PR didn't tell us they were doing it this way...seems now the drug trial won't end until about Sept...oh well

Drug trial should be nearly complete
...will help us

PRFX under $2

PRFX 10Q due March 14

Come on back to PRFX...it needs you...up, up and away it's going

PRFX is on the march...up 1,2,3,4....up 1,2,3,4

Waking up for those who listen...( Actually I feel I'm talking to myself, if so, I will be the one making all d- money lol)

Way oversold here...a big pop is coming soon

GL

Yeah, I like the story. Right now I'm going with "what is" and not "what if".

PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second part of the Company’s phase 3 trial to evaluate PRF-110 in patients undergoing bunionectomy surgery.

Starting the second part of the bunionectomy Phase III study follows the clearance by FDA of the DMF (Drug Master File) held by the Company’s API manufacturer. This second part of the trial is expected to proceed in the next quarter of 2023.

As announced earlier this year, the company completed the first part of its Phase 3 clinical trial of PRF-110, in which 15 patients undergoing bunionectomy surgery were enrolled at two clinical sites in Texas. The Company reported positive safety data in the first part of the Phase 3 clinical trial with no serious adverse events (SAEs) reported, suggesting a substantial potential advantage to using PRF-110 over opioids. As previously reported, PRF-110 provided pain reduction for up to 72 hours post-operatively in the Company’s prior Phase 2 proof-of-concept clinical study in herniorrhaphy (hernia repair).

The upcoming second part of the trial will be a double-blind study, in which the Company plans to randomize approximately 400 patients at seven clinical sites in the U.S.

PRF-110 is a highly uniform solution, resulting in consistent sustained and extended release of the analgesic. Ropivacaine, the active drug used in PRF-110, is a safe, well-tolerated, and well-characterized local anesthetic. The other components that comprise the remainder of the PRF-110 formulation have been designated by the FDA as Generally Recognized as Safe (GRAS), mitigating many potential safety issues common in drug development.

Key surgical benefits observed to date include:

PRF-110 does not alter the integrity of standard surgical devices, such as sutures and meshes used in a large variety of surgical procedures

PRF-110 does not interfere with normal macro and microscopic wound healing of surgical incisions in soft tissue and bone models

PRF-110 does not alter the tensile strength of healed skin at the surgical sites in an animal study mimicking surgical procedures

Ilan Hadar, Chief Executive Officer of PainReform, stated, “We expect to commence the second part of our phase 3 clinical study in Q4, 2023 following positive pharmacokinetic (PK) data in the first part of our Phase 3 clinical trial of PRF-110 in bunionectomy, which exceeded the FDA safety requirements.   This data reinforces the favorable results of our prior Phase 2 data in hernia repair, which provides us confidence in the outlook for PRF-110. Although we encountered delays due to issues experienced by the manufacturer of our API (active pharmaceutical ingredient), unrelated to PFR-110, we worked closely with them to rapidly resolve these matters, and our clinical program is now back on track. following a positive completion of the DMF review by the FDA. We look forward to advancing the trial, which we expect to complete and report the results by mid-2024. Importantly, we believe PRF-110 has the potential to address a significant unmet need in the multi-billion postoperative pain market with the potential to become standard of care as an alternative to systemic opioids.”

About PainReform

PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates. For more information, please visit www.painreform.com.

I sold. Too speculative. And I need the money elsewhere. GL

Starting to accumulate more...oversold

PRFX new 52 week low

Just opened a small position. Interesting stock. Venture capital only...

You said it buddy...it won't be for long

Good deal

Added more today

Waiting on reversal.

Looks bottomed

Could be $100+ after phase 3 drug trial ends...soon

It's a good day to add PRFX to your portfolio...it's dirt cheap

Enjoy yur day

PRFX is undervalued, this price shouldn't be where it is now.